Cipla Ltd. — Regulatory Filings 2021

May 14, 2021

14th May, 2021

• (1) BSE Limited Listing Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001
• (2) National Stock Exchange of India Limited Listing Department Exchange Plaza, 5th floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051

Scrip Code: 500087

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg

Sub: Investor Presentation

Dear Sir/ Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed investor presentation dated 14th May, 2021.

This is for your information and record.

Thanking you,

Yours faithfully,

For Cipla Limited Rajendra Chopra Company Secretary RAJEND RA CHOPRA Digitally signed by RAJENDRA CHOPRA Date: 2021.05.14 18:44:21 +05'30'

Encl: as above Prepared by: Nishtha Agarwal

Investor Presentation

Q4FY21

14-5-2021

CLICK TO EDIT MASTER TITLE STYLE DISCLAIMER

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties including impact of Covid-19 and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.

The investor presentation is not intended to endorse, advertise, promote or recommend the use of any products listed in it which are for representation purpose only, some of which are reference listed drugs of which the Company has approved, under approval or under development generic equivalents. The prefixes "g" and "generic" used interchangeably indicate the generic versions of the named brand drugs.

Information relating to any medical products or medical devices contained herein is provided by Cipla for general information purposes only. Information on any of the medical products or medical devices may vary from country-to-country. A reference to a medical product or a medical device does not imply that such medical product or medical device is available in your country. The commercial availability of the medical products or medical devices listed herein in your country is dependent on the validity and status of existing patents and/or marketing authorizations related to each. An independent enquiry regarding the availability of each medical products or medical device should be made for each individual country.

The product information contained herein is not intended to provide complete medical information, and is not intended to be used as an alternative to consulting with qualified doctors or health care professionals.

Nothing contained herein should be construed as giving of advice or the making of a recommendation and it should not be relied on as the basis for any decision or action. It is important to only rely on the advice of a health care professional.

CLICK TO EDIT MASTER TITLE STYLE We continue to remain at the forefront in the fight against COVID-19 and delivering on our promise of 'Caring for life'

Ramping up capacities to maintain supply

❖ Remdesivir monthly supplies being ramped up to ~5x of supplies in previous peak phase of the pandemic

Cipremi® Remdesivir

Budecort® Budesonide

❖ Ensuring availability of ICMR¹ recommended Inhaled Budesonide for Covid-19 patients

Increasing treatments options with new collaborations for innovative medicines for Covid-19

Molnupiravir

• ❖ Partnership with Merck & Co., Inc. for manufacturing & distribution of investigational oral antiviral drug Molnupiravir, currently in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19
• ❖ Covered geographies include India and 100+ low to middle income countries

Casirivimab and Imdevimab

• ❑ Partnership with Roche for pan India distribution of antibody cocktail (Casirivimab and Imdevimab)
• ❑ Indicated for the treatment of mild to moderate Covid-19 in high-risk patients

Baricitinib

• ❑ Partnership with Eli Lilly & Company, USA for manufacture and commercialization of the drug baricitinib
• ❑ Indicated for use in combination with Remdesivir for the treatment COVID-19 in hospitalized adults

CLICK TO EDIT MASTER TITLE STYLE Continued focus on maintaining a strong balance sheet health and robust free cash flow generation

• Continued governance on cash and liquidity management
• Optimised capex and working capital efficiencies drive robust free cash flow generation

• Net cash positive position continues at March-21 end reflects strong balance sheet health

• included cash and cash equivalents and current investments excluding unclaimed dividend balances

CLICK TO EDIT MASTER TITLE STYLE Q4 performance demonstrates sustained performance and operational resiliency

Financial Performance – Q4FY21

Revenues	INR 4,606 Cr		5%
		Actuals (Rs Cr)	vs Q4 FY 20
Total Revenue from Operations		4,606	5%
EBITDA		796	22%
EBITDA % of revenue		17.3%	239 bps
PAT		413	68%
PAT % of revenue		9.0%	335 bps

R&D INR 277 Cr Focused R&D investments

1. Sri Lanka, Myanmar, Nepal and Morocco 1 India includes Rx + Gx+ CHL; SAGA includes South Africa, Sub-Saharan Africa and Cipla Global Access; Figures have been rounded-off

Financial Performance – FY21

Revenues	INR 19,160 Cr		12%
		Actuals (Rs Cr)	vs FY 20
Total Revenue from Operations		19,160	12%
EBITDA2		4,303	33%
EBITDA % of revenue		22.5%	361 bps
PAT		2,405	56%
PAT % of revenue		12.6%	352 bps

R&D INR 924 Cr Focused R&D investments

1. As per IQVIA 2. Sri Lanka, Myanmar, Nepal and Morocco 1 India includes Rx + Gx+ CHL; SAGA includes South Africa, Sub-Saharan Africa and Cipla Global Access; Figures have been rounded-off │2. Includes one-time income from a litigation settlement in Q3FY21

CLICK TO EDIT MASTER TITLE STYLE One India (Rx + Gx+ CHL¹ ): Consistent execution driving growth across businesses in India

Key Business Highlights

Prescription business

• ❖ Sequential normalization in-line with expectations
• ❖ Significantly expanding covid portfolio with partnerships
• ❖ Healthy volume trends emerging in core portfolio

Therapy2	Market Rank	Market share	Cipla Growth	Market growth
Overall Chronic	2	• 9 8.1%	12%	8%
Respiratory	1	24.6%	4%	-8%
Urology	1	14.8%	7%	4%
Cardiac	4	5.4%	10%	13%
Derma	11	2.7%	8%	6%

Trade generics business

• ❖ Healthy order flow across regions during the quarter
• ❖ Strong demand tailwinds emerging across portfolio

Consumer health business

• ❖ Continued traction in consumer brands post transfer from trade generics business;

• ❖ Cipladine brand transferred from trade generics

• CHL – Cipla Health Limited │2. Market data as per IQVIA IMS MAT'21

INR 360 Cr (FY21 Revenue)

Global consumer health franchise

6%+ contribution to overall revenues in FY21; momentum to achieve long term aspirations

1. Market data as per Nielsen; *nicotine replacement therapy

CLICK TO EDIT MASTER TITLE STYLE SAGA¹ : South Africa, Sub-Saharan Africa and Cipla Global Access

1. Financial numbers are rounded off │2. Market data as per IQVIA MAT Mar'21

SA

overall

CLICK TO EDIT MASTER TITLE STYLE North America: Continued traction in respiratory and complex generics portfolio

Key Business Highlights

US Generics ramp-up continues

• ❖ Continued market share expansion in overall Albuterol market and growth in institutional business
• ❖ New approval: Sumatriptan nasal spray 20mg
• ❖ Full year FY21 EBITDA margins tracking close to overall company level

Albuterol HFA market1 segment	• 1 2 TRx Market Rank	TRx Market share
gProventil	1	~87%
Generic market (AG + Gx)	3	16.5%
Total market (Brand + AG + Gx)	3	13.2%

• ❖ Closely working with USFDA on gAdvair
• ❖ 2 Partnered peptide injectable filings during in FY21; includes one new drug application

1. Market data as per IQVIA week ending 23rd April 2021

2 PEPFAR approved ANDAs can be commercialised in US

Emerging Markets, Europe and API

CLICK TO EDIT MASTER TITLE STYLE Our FY22 priorities include

Ramping up Covid portfolio supply to increase availability and maximize patients reach

Maintain market beating growth in large branded and unbranded generic franchises of India, South Africa and augment consumer wellness franchise

Expanding lung leadership globally and maximising value opportunity in US complex generics by prioritizing key launches with focused execution and collaborating with regulatory authorities

Scaling up businesses across branded and generic DTMs of Europe and Emerging markets through execution on organic and partnered launches including biosimilars

Accelerating digital transformation to capitalize opportunities and growth opportunities across markets

Focus on regulatory compliance across manufacturing locations and embrace best-in class globally benchmarked ESG¹ practices

Sustained expansion in RoIC over the long term

1. Environmental, Social and Governance

Thank You

Registered Office :

Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013

For any queries, please contact Naveen Bansal Investor.Relations@cipla.com

For more information please visit www.cipla.com